[{"data":1,"prerenderedAt":81},["ShallowReactive",2],{"topic-policy-access":3},{"articles":4,"guides":80},[5],{"id":6,"title":7,"author":8,"authorTitle":9,"body":10,"date":66,"description":67,"draft":68,"extension":69,"featured":68,"heroCredit":70,"heroImage":71,"meta":72,"navigation":73,"path":74,"readingTime":75,"seo":76,"stem":77,"topic":78,"__hash__":79},"articles\u002Farticles\u002Fwho-gets-to-be-a-patient.md","Who gets to be a patient?","Tomas Iwu","health policy researcher",{"type":11,"value":12,"toc":58},"minimark",[13,17,22,25,31,35,38,42,55],[14,15,16],"p",{},"Suppose the optimistic version comes true and one or more psychedelic therapies\nare approved for serious, hard-to-treat conditions. A quieter question\nimmediately follows the celebratory one: who, in practice, will actually be able\nto receive them?",[18,19,21],"h2",{"id":20},"a-labour-intensive-treatment-is-an-access-problem","A labour-intensive treatment is an access problem",[14,23,24],{},"These are not pills you collect from a pharmacy. The model under study involves\ntrained clinicians, long preparation, supervised dosing, and integration over\nweeks. That is expensive and slow by design. Left to the market alone, a\ntreatment with those properties tends to reach the affluent and well-connected\nfirst, and everyone else much later, if at all.",[26,27,28],"blockquote",{},[14,29,30],{},"A therapy that only the comfortable can afford does not reduce suffering. It\nredistributes it upward.",[18,32,34],{"id":33},"the-pattern-we-have-seen-before","The pattern we have seen before",[14,36,37],{},"New psychiatric treatments have a history of arriving unevenly — concentrated in\nwealthy areas, under-available to the communities carrying the heaviest burden\nof untreated illness. There is no law of nature that says this must repeat. But\nit will repeat by default unless access is designed for deliberately.",[18,39,41],{"id":40},"what-designing-for-access-looks-like","What designing for access looks like",[43,44,45,49,52],"ul",{},[46,47,48],"li",{},"Training pathways that do not restrict this work to a small, costly elite.",[46,50,51],{},"Coverage decisions that consider need, not only ability to pay.",[46,53,54],{},"Research populations that resemble the people who will eventually need care,\nso the evidence actually generalises to them.",[14,56,57],{},"The scientific question — does it work? — is being taken seriously. The\ndistributive question — for whom? — deserves the same seriousness, and it has to\nbe asked now, while the answers can still be shaped.",{"title":59,"searchDepth":60,"depth":60,"links":61},"",3,[62,64,65],{"id":20,"depth":63,"text":21},2,{"id":33,"depth":63,"text":34},{"id":40,"depth":63,"text":41},"2026-04-02","If psychedelic therapy becomes a real treatment, the next question is not whether it works but who will be able to reach it — and whether access will follow need or money.",false,"md","Higher Place — original artwork","\u002Fimg\u002Fheroes\u002Fpolicy-access.svg",{},true,"\u002Farticles\u002Fwho-gets-to-be-a-patient",7,{"title":7,"description":67},"articles\u002Fwho-gets-to-be-a-patient","policy-access","lyUggA-5dlyQ4AvUFAMhxqyS9BNeOEKCgQvKmW5YS2k",[],1779224636839]